139 related articles for article (PubMed ID: 38171010)
1. A Novel Gain-of-Signal Assay to Detect Targeted Protein Degradation.
Hoffman M; Cheah KMH; Wittrup KD
ACS Synth Biol; 2024 Jan; 13(1):220-229. PubMed ID: 38171010
[TBL] [Abstract][Full Text] [Related]
2. Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein.
Wang M; Lu J; Wang M; Yang CY; Wang S
J Med Chem; 2020 Jul; 63(14):7510-7528. PubMed ID: 32437146
[TBL] [Abstract][Full Text] [Related]
3. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
4. Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders.
Yang X; Wang Z; Pei Y; Song N; Xu L; Feng B; Wang H; Luo X; Hu X; Qiu X; Feng H; Yang Y; Zhou Y; Li J; Zhou B
Eur J Med Chem; 2021 Jun; 218():113341. PubMed ID: 33780898
[TBL] [Abstract][Full Text] [Related]
5. A practical "preTACs-cytoblot" platform accelerates the streamlined development of PROTAC-based protein degraders.
Rao Z; Li K; Hong J; Chen D; Ding B; Jiang L; Qi X; Hu J; Yang B; He Q; Dong X; Cao J; Zhu CL
Eur J Med Chem; 2023 May; 251():115248. PubMed ID: 36905918
[TBL] [Abstract][Full Text] [Related]
6. Targeted Protein Degradation: Design Considerations for PROTAC Development.
Tran NL; Leconte GA; Ferguson FM
Curr Protoc; 2022 Dec; 2(12):e611. PubMed ID: 36469581
[TBL] [Abstract][Full Text] [Related]
7. A Novel Lysosome Targeting Chimera for Targeted Protein Degradation via Split-and-Mix Strategy.
Wang J; Wang Y; Yang F; Luo Q; Hou Z; Xing Y; Lu F; Li Z; Yin F
ACS Chem Biol; 2024 May; 19(5):1161-1168. PubMed ID: 38662199
[TBL] [Abstract][Full Text] [Related]
8. Development of Human Carbonic Anhydrase II Heterobifunctional Degraders.
O'Herin CB; Moriuchi YW; Bemis TA; Kohlbrand AJ; Burkart MD; Cohen SM
J Med Chem; 2023 Feb; 66(4):2789-2803. PubMed ID: 36735827
[TBL] [Abstract][Full Text] [Related]
9. Development of selective FGFR1 degraders using a Rapid synthesis of proteolysis targeting Chimera (Rapid-TAC) platform.
Guo L; Liu J; Nie X; Wang T; Ma ZX; Yin D; Tang W
Bioorg Med Chem Lett; 2022 Nov; 75():128982. PubMed ID: 36096343
[TBL] [Abstract][Full Text] [Related]
10. Simple Structural Modifications Converting a Bona fide MDM2 PROTAC Degrader into a Molecular Glue Molecule: A Cautionary Tale in the Design of PROTAC Degraders.
Yang J; Li Y; Aguilar A; Liu Z; Yang CY; Wang S
J Med Chem; 2019 Nov; 62(21):9471-9487. PubMed ID: 31560543
[TBL] [Abstract][Full Text] [Related]
11. Targeting oncoproteins with a positive selection assay for protein degraders.
Koduri V; Duplaquet L; Lampson BL; Wang AC; Sabet AH; Ishoey M; Paulk J; Teng M; Harris IS; Endress JE; Liu X; Dasilva E; Paulo JA; Briggs KJ; Doench JG; Ott CJ; Zhang T; Donovan KA; Fischer ES; Gygi SP; Gray NS; Bradner J; Medin JA; Buhrlage SJ; Oser MG; Kaelin WG
Sci Adv; 2021 Feb; 7(6):. PubMed ID: 33547076
[TBL] [Abstract][Full Text] [Related]
12. Emerging mechanisms of targeted protein degradation by molecular glues.
Frere GA; de Araujo ED; Gunning PT
Methods Cell Biol; 2022; 169():1-26. PubMed ID: 35623698
[TBL] [Abstract][Full Text] [Related]
13. The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation.
Riching KM; Caine EA; Urh M; Daniels DL
Chem Soc Rev; 2022 Jul; 51(14):6210-6221. PubMed ID: 35792307
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology.
Mukhamejanova Z; Tong Y; Xiang Q; Xu F; Pang J
Curr Med Chem; 2021; 28(7):1304-1327. PubMed ID: 32164504
[TBL] [Abstract][Full Text] [Related]
15. Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development.
Donovan KA; Ferguson FM; Bushman JW; Eleuteri NA; Bhunia D; Ryu S; Tan L; Shi K; Yue H; Liu X; Dobrovolsky D; Jiang B; Wang J; Hao M; You I; Teng M; Liang Y; Hatcher J; Li Z; Manz TD; Groendyke B; Hu W; Nam Y; Sengupta S; Cho H; Shin I; Agius MP; Ghobrial IM; Ma MW; Che J; Buhrlage SJ; Sim T; Gray NS; Fischer ES
Cell; 2020 Dec; 183(6):1714-1731.e10. PubMed ID: 33275901
[TBL] [Abstract][Full Text] [Related]
16. Protein degraders enter the clinic - a new approach to cancer therapy.
Chirnomas D; Hornberger KR; Crews CM
Nat Rev Clin Oncol; 2023 Apr; 20(4):265-278. PubMed ID: 36781982
[TBL] [Abstract][Full Text] [Related]
17. Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway.
Ottis P; Palladino C; Thienger P; Britschgi A; Heichinger C; Berrera M; Julien-Laferriere A; Roudnicky F; Kam-Thong T; Bischoff JR; Martoglio B; Pettazzoni P
ACS Chem Biol; 2019 Oct; 14(10):2215-2223. PubMed ID: 31553577
[TBL] [Abstract][Full Text] [Related]
18. The state of the art of PROTAC technologies for drug discovery.
Wang C; Zheng C; Wang H; Zhang L; Liu Z; Xu P
Eur J Med Chem; 2022 May; 235():114290. PubMed ID: 35307618
[TBL] [Abstract][Full Text] [Related]
19. Targeted Degradation of the Oncogenic Phosphatase SHP2.
Vemulapalli V; Donovan KA; Seegar TCM; Rogers JM; Bae M; Lumpkin RJ; Cao R; Henke MT; Ray SS; Fischer ES; Cuny GD; Blacklow SC
Biochemistry; 2021 Aug; 60(34):2593-2609. PubMed ID: 34411482
[TBL] [Abstract][Full Text] [Related]
20. Development of decoy oligonucleotide-warheaded chimeric molecules targeting STAT3.
Shih PC; Naganuma M; Tsuji G; Demizu Y; Naito M
Bioorg Med Chem; 2023 Nov; 95():117507. PubMed ID: 37922656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
